[en] INTRODUCTION: Primary hyperoxaluria type 1 (PH1) has a highly heterogeneous disease course. Apart from the c.508G>A (p.Gly170Arg) AGXT variant, which imparts a relatively favorable outcome, little is known about determinants of kidney failure. Identifying these is crucial for disease management, especially in this era of new therapies. METHODS: In this retrospective study of 932 patients with PH1 included in the OxalEurope registry, we analyzed genotype-phenotype correlations as well as the impact of nephrocalcinosis, urolithiasis, and urinary oxalate and glycolate excretion on the development of kidney failure, using survival and mixed model analyses. RESULTS: The risk of developing kidney failure was the highest for 175 vitamin-B6 unresponsive ("null") homozygotes and lowest for 155 patients with c.508G>A and c.454T>A (p.Phe152Ile) variants, with a median age of onset of kidney failure of 7.8 and 31.8 years, respectively. Fifty patients with c.731T>C (p.Ile244Thr) homozygote variants had better kidney survival than null homozygotes (P = 0.003). Poor outcomes were found in patients with other potentially vitamin B6-responsive variants. Nephrocalcinosis increased the risk of kidney failure significantly (hazard ratio [HR] 3.17 [2.03-4.94], P < 0.001). Urinary oxalate and glycolate measurements were available in 620 and 579 twenty-four-hour urine collections from 117 and 87 patients, respectively. Urinary oxalate excretion, unlike glycolate, was higher in patients who subsequently developed kidney failure (P = 0.034). However, the 41% intraindividual variation of urinary oxalate resulted in wide confidence intervals. CONCLUSION: In conclusion, homozygosity for AGXT null variants and nephrocalcinosis were the strongest determinants for kidney failure in PH1.
Disciplines :
Urologie & néphrologie
Auteur, co-auteur :
Metry, Elisabeth L; Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Garrelfs, Sander F; Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Deesker, Lisa J; Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Acquaviva, Cecile; Service de Biochimie et Biologie Moléculaire, UM Pathologies Héréditaires du Métabolisme et du Globule Rouge, Hospices Civils de Lyon, France.
D'Ambrosio, Viola; Department of Nephrology, Catholic University of the Sacred Heart, Rome, Italy.
Bacchetta, Justine; Centre de Référence des Maladies Rares Néphrogones, Hospices Civils de Lyon et Université Claude-Bernard Lyon 1, Lyon, France.
Beck, Bodo B; Institute of Human Genetics, Center for Molecular Medicine Cologne, University Hospital of Cologne, Cologne, Germany. ; Center for Rare and Hereditary Kidney Disease Cologne, University Hospital of Cologne, Cologne, Germany.
Cochat, Pierre; Centre de Référence des Maladies Rares Néphrogones, Hospices Civils de Lyon et Université Claude-Bernard Lyon 1, Lyon, France.
Collard, Laure ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pédiatrie
Hogan, Julien; Department of Pediatric Nephrology, Assistance Publique-Hôpitaux de Paris Robert-Debré, University of Paris, Paris, France.
Ferraro, Pietro Manuel; Department of Nephrology, Catholic University of the Sacred Heart, Rome, Italy.
Franssen, Casper F M; Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Harambat, Jérôme; Department of Pediatrics, Pediatric Nephrology Unit, Bordeaux University Hospital, Bordeaux, France.
Hulton, Sally-Anne; Department of Nephrology, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, UK.
Lipkin, Graham W; Department of Nephrology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Mandrile, Giorgia; Genetic Unit and Thalassemia Center, San Luigi University Hospital, Orbassano, Italy.
Martin-Higueras, Cristina; Institute of Biomedical Technology, CIBERER, University of Laguna, San Cristóbal de La Laguna, Spain.
Mohebbi, Nilufar; Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
Moochhala, Shabbir H; UCL Department of Renal Medicine, Royal Free Hospital, London, UK.
Neuhaus, Thomas J; Department of Pediatrics, Children's Hospital Lucerne, Lucerne, Switzerland.
Prikhodina, Larisa; Department of Inherited and Acquired Kidney Diseases, Veltishev Research and Clinical Institute for Pediatrics and Pediatric Surgery of the Pirogov Russian National Research Medical University, Moscow, Russia.
Salido, Eduardo; Department of Pathology, Center for Biomedical Research on Rare Diseases, Hospital Universitario Canarias, Universidad La Laguna, Tenerife, Spain.
Topaloglu, Rezan; Division of Pediatric Nephrology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Oosterveld, Michiel J S; Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Groothoff, Jaap W; Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Peters-Sengers, Hessel; Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Hopp, K., Cogal, A.G., Bergstralh, E.J., et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26 (2015), 2559–2570, 10.1681/asn.2014070698.
Almardini, R.I., Alfarah, M.G., Salaita, G.M., The clinical pattern of primary hyperoxaluria in pediatric patient at Queen Rania Abdulla Children Hospital. Arab J Nephrol Transplant 7 (2014), 119–123.
Boussetta, A., Karray, A., Abida, N., Jellouli, M., Gargah, T., Monogenic urinary lithiasis in Tunisian children: 25 years’ experience of a referral center. Tunis Med 100 (2022), 410–415.
Stenson, P.D., Mort, M., Ball, E.V., et al. The human gene mutation database (HGMD®): optimizing its use in a clinical diagnostic or research setting. Hum Genet 139 (2020), 1197–1207, 10.1007/s00439-020-02199-3.
Fargue, S., Rumsby, G., Danpure, C.J., Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 1832:10 (2013), 1776–1783, 10.1016/j.bbadis.2013.04.010.
Mandrile, G., van Woerden, C.S., Berchialla, P., et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 86 (2014), 1197–1204, 10.1038/ki.2014.222.
Fargue, S., Acquaviva Bourdain, C., Primary hyperoxaluria type 1: pathophysiology and genetics. Clin Kidney J 15:suppl 1 (2022), i4–i8, 10.1093/ckj/sfab217.
Tang, X., Bergstralh, E.J., Mehta, R.A., Vrtiska, T.J., Milliner, D.S., Lieske, J.C., Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int 87 (2015), 623–631, 10.1038/ki.2014.298.
van Woerden, C.S., Groothoff, J.W., Wanders, R.J., Davin, J.C., Wijburg, F.A., Primary hyperoxaluria type 1 in the Netherlands: prevalence and outcome. Nephrol Dial Transplant 18 (2003), 273–279, 10.1093/ndt/18.2.273.
Milliner, D.S., McGregor, T.L., Thompson, A., et al. End points for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol 15 (2020), 1056–1065, 10.2215/cjn.13821119.
Mandrile, G., Beck, B., Acquaviva, C., et al. Genetic assessment in primary hyperoxaluria: why it matters. Pediatr Nephrol 38 (2023), 625–634, 10.1007/s00467-022-05613-2.
Hoppe, B., Beck, B.B., Milliner, D.S., The primary hyperoxalurias. Kidney Int 75 (2009), 1264–1271, 10.1038/ki.2009.32.
Clifford-Mobley, O., Sjögren, A., Lindner, E., Rumsby, G., Urine oxalate biological variation in patients with primary hyperoxaluria. Urolithiasis 44 (2016), 333–337, 10.1007/s00240-016-0860-2.
van Woerden, C.S., Groothoff, J.W., Wijburg, F.A., Annink, C., Wanders, R.J., Waterham, H.R., Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int 66 (2004), 746–752, 10.1111/j.1523-1755.2004.00796.x.
Santana, A., Salido, E., Torres, A., Shapiro, L.J., Primary hyperoxaluria type 1 in the Canary Islands: a conformational disease due to I244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc Natl Acad Sci U S A 100 (2003), 7277–7282, 10.1073/pnas.1131968100.
Medina, P.G., Román, L.E., Importance of assessing compliance with conservative treatment of primary hyperoxaluria type 1: a case report of a patient with I244T/c.969-3C>G Mutation. Perm J 24 (2020), 19–136, 10.7812/tpp/19.136.
Lorenzo, V., Alvarez, A., Torres, A., Torregrosa, V., Hernández, D., Salido, E., Presentation and role of transplantation in adult patients with type 1 primary hyperoxaluria and the I244T AGXT mutation: single-center experience. Kidney Int 70 (2006), 1115–1119, 10.1038/sj.ki.5001758.
Oppici, E., Fargue, S., Reid, E.S., et al. Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I. Hum Mol Genet 24 (2015), 5500–5511, 10.1093/hmg/ddv276.
Cellini, B., Montioli, R., Voltattorni, C.B., Human liver peroxisomal alanine:glyoxylate aminotransferase: characterization of the two allelic forms and their pathogenic variants. Biochim Biophys Acta 1814:11 (2011), 1577–1584, 10.1016/j.bbapap.2010.12.005.
Singh, P., Chebib, F.T., Cogal, A.G., Gavrilov, D.K., Harris, P.C., Lieske, J.C., Pyridoxine responsiveness in a Type 1 primary hyperoxaluria patient with a rare (atypical) AGXT gene mutation. Kidney Int Rep 5 (2020), 955–958, 10.1016/j.ekir.2020.04.004.
Dindo, M., Mandrile, G., Conter, C., et al. The ILE56 mutation on different genetic backgrounds of alanine:glyoxylate aminotransferase: clinical features and biochemical characterization. Mol Genet Metab 131 (2020), 171–180, 10.1016/j.ymgme.2020.07.012.
Montioli, R., Oppici, E., Dindo, M., et al. Misfolding caused by the pathogenic mutation G47R on the minor allele of alanine:glyoxylate aminotransferase and chaperoning activity of pyridoxine. Biochim Biophys Acta 10:1854 (2015), 1280–1289, 10.1016/j.bbapap.2015.07.002.
Oppici, E., Roncador, A., Montioli, R., Bianconi, S., Cellini, B., Gly161 mutations associated with Primary Hyperoxaluria Type I induce the cytosolic aggregation and the intracellular degradation of the apo-form of alanine:glyoxylate aminotransferase. Biochim Biophys Acta 1832 (2013), 2277–2288, 10.1016/j.bbadis.2013.09.002.
Hoyer-Kuhn, H., Kohbrok, S., Volland, R., et al. Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol 9 (2014), 468–477, 10.2215/cjn.06820613.
Zhao, F., Bergstralh, E.J., Mehta, R.A., et al. Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11 (2016), 119–126, 10.2215/cjn.02810315.
Balchin, Z.E., Moss, P.A., Fraser, C.G., Biological variation of urinary oxalate in different specimen types. Ann Clin Biochem 28 (1991), 622–623, 10.1177/000456329102800615.
Groothoff, J.W., Metry, E., Deesker, L., et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol 19 (2023), 194–211, 10.1038/s41581-022-00661-1.
Osswald, H., Hautmann, R., Renal elimination kinetics and plasma half-life of oxalate in man. Urol Int 34 (1979), 440–450, 10.1159/000280294.
